Alexandria Real Estate Equities, Inc. Elects Claire Aldridge, PhD, to Board of Directors
Alexandria Real Estate Equities (NYSE: ARE) has elected Claire Aldridge, PhD, to its Board of Directors, effective March 14, 2025. Dr. Aldridge will serve as a member of the Life Science Committee, with her term running until the company's 2025 annual meeting.
Dr. Aldridge brings over 25 years of experience in biotechnology, venture capital, entrepreneurship, and AI-accelerated therapeutic development. She previously served as chief strategy officer at Form Bio, where she led AI and machine learning integration for genomic analysis. Her prior roles include senior positions at Taysha Gene Therapies, UT Southwestern Medical Center, and Remeditex Ventures.
Currently, she serves on multiple boards including Colossal Biosciences' scientific advisory board and 4E Therapeutics' board of directors. She was recognized as one of Forbes' 10 women leading the synthetic biology revolution in April 2023.
Alexandria Real Estate Equities (NYSE: ARE) ha eletto Claire Aldridge, PhD, nel suo Consiglio di Amministrazione, con effetto dal 14 marzo 2025. La Dr.ssa Aldridge sarà membro del Comitato per le Scienze della Vita, con un mandato che durerà fino all'assemblea annuale dell'azienda del 2025.
La Dr.ssa Aldridge porta con sé oltre 25 anni di esperienza nel settore della biotecnologia, del capitale di rischio, dell'imprenditorialità e dello sviluppo terapeutico accelerato dall'IA. In precedenza, ha ricoperto il ruolo di chief strategy officer presso Form Bio, dove ha guidato l'integrazione dell'IA e dell'apprendimento automatico per l'analisi genomica. Le sue esperienze precedenti includono posizioni di rilievo presso Taysha Gene Therapies, UT Southwestern Medical Center e Remeditex Ventures.
Attualmente, è membro di diversi consigli, tra cui il consiglio consultivo scientifico di Colossal Biosciences e il consiglio di amministrazione di 4E Therapeutics. È stata riconosciuta come una delle 10 donne di Forbes che guidano la rivoluzione della biologia sintetica nell'aprile 2023.
Alexandria Real Estate Equities (NYSE: ARE) ha elegido a Claire Aldridge, PhD, para su Junta Directiva, con efecto a partir del 14 de marzo de 2025. La Dra. Aldridge será miembro del Comité de Ciencias de la Vida, con un mandato que se extenderá hasta la reunión anual de la empresa en 2025.
La Dra. Aldridge aporta más de 25 años de experiencia en biotecnología, capital de riesgo, emprendimiento y desarrollo terapéutico acelerado por IA. Anteriormente, se desempeñó como directora de estrategia en Form Bio, donde lideró la integración de IA y aprendizaje automático para el análisis genómico. Sus roles anteriores incluyen posiciones de alto nivel en Taysha Gene Therapies, UT Southwestern Medical Center y Remeditex Ventures.
Actualmente, forma parte de varias juntas, incluyendo la junta asesora científica de Colossal Biosciences y la junta directiva de 4E Therapeutics. Fue reconocida como una de las 10 mujeres de Forbes que lideran la revolución de la biología sintética en abril de 2023.
알렉산드리아 리얼 에스테이트 이퀴티스 (NYSE: ARE)가 클레어 올드리지 박사를 이사로 선임했으며, 이는 2025년 3월 14일부터 효력이 발생합니다. 올드리지 박사는 생명과학 위원회의 일원으로 활동하며, 그녀의 임기는 회사의 2025년 연례 회의까지 지속됩니다.
올드리지 박사는 생명공학, 벤처 캐피탈, 기업가 정신 및 AI 가속 치료 개발 분야에서 25년 이상의 경험을 보유하고 있습니다. 그녀는 이전에 Form Bio에서 최고 전략 책임자로 재직하며 유전체 분석을 위한 AI 및 머신러닝 통합을 이끌었습니다. 그녀의 이전 경력에는 Taysha Gene Therapies, UT Southwestern Medical Center 및 Remeditex Ventures에서의 고위직이 포함됩니다.
현재 그녀는 Colossal Biosciences의 과학 자문 위원회와 4E Therapeutics의 이사회 등 여러 이사회에서 활동하고 있습니다. 그녀는 2023년 4월 포브스가 선정한 합성 생물학 혁명을 이끄는 10명의 여성 중 한 명으로 인정받았습니다.
Alexandria Real Estate Equities (NYSE: ARE) a élu Claire Aldridge, PhD, à son Conseil d'Administration, avec effet au 14 mars 2025. Dr. Aldridge sera membre du Comité des Sciences de la Vie, et son mandat se poursuivra jusqu'à l'assemblée générale de l'entreprise en 2025.
Dr. Aldridge apporte plus de 25 ans d'expérience dans les domaines de la biotechnologie, du capital-risque, de l'entrepreneuriat et du développement thérapeutique accéléré par l'IA. Elle a précédemment occupé le poste de directrice de la stratégie chez Form Bio, où elle a dirigé l'intégration de l'IA et de l'apprentissage automatique pour l'analyse génomique. Ses rôles précédents incluent des postes de direction chez Taysha Gene Therapies, UT Southwestern Medical Center et Remeditex Ventures.
Actuellement, elle siège à de nombreux conseils, y compris le conseil consultatif scientifique de Colossal Biosciences et le conseil d'administration de 4E Therapeutics. Elle a été reconnue comme l'une des 10 femmes de Forbes qui dirigent la révolution de la biologie synthétique en avril 2023.
Alexandria Real Estate Equities (NYSE: ARE) hat Claire Aldridge, PhD, in seinen Vorstand gewählt, mit Wirkung zum 14. März 2025. Dr. Aldridge wird Mitglied des Lebenswissenschaftsausschusses sein, und ihre Amtszeit läuft bis zur Hauptversammlung des Unternehmens im Jahr 2025.
Dr. Aldridge bringt über 25 Jahre Erfahrung in den Bereichen Biotechnologie, Risikokapital, Unternehmertum und KI-unterstützte Therapeutikentwicklung mit. Zuvor war sie Chief Strategy Officer bei Form Bio, wo sie die Integration von KI und maschinellem Lernen für die genomische Analyse leitete. Zu ihren vorherigen Positionen gehören leitende Funktionen bei Taysha Gene Therapies, UT Southwestern Medical Center und Remeditex Ventures.
Derzeit ist sie in mehreren Gremien tätig, darunter im wissenschaftlichen Beratungsgremium von Colossal Biosciences und im Vorstand von 4E Therapeutics. Sie wurde im April 2023 als eine der 10 Frauen von Forbes, die die Revolution der synthetischen Biologie anführen, anerkannt.
- Board strengthened with 25+ years life science industry expertise
- Addition of AI and machine learning expertise in genomic analysis
- Enhanced biotechnology and venture capital experience on board
- Independent director appointment improving corporate governance
- None.
"Dr. Aldridge's distinguished career in the life science industry spans more than 25 years across biotechnology, venture capital, entrepreneurship, technology commercialization and AI-accelerated therapeutic development," said Joel S. Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments. "Her deep business and scientific experience, which includes facilitating the translation of scientific discoveries into innovative therapies that improve patient lives, will further bolster the combined expertise of our board, and we are honored to welcome her."
Dr. Aldridge was the chief strategy officer of Form Bio, the first spinout from the de-extinction and biodiversity company Colossal Biosciences. At Form Bio, Dr. Aldridge led the integration of artificial intelligence and machine learning into genomic analysis and advanced therapeutics programs, such as gene therapy, biological sequence alignment and directed evolution, to accelerate the development of safe and effective new medicines. She also oversaw the generation of vast proprietary datasets needed to train sophisticated AI models. Prior to Form Bio, Dr. Aldridge served as senior vice president, chief of staff and business operations at Taysha Gene Therapies, a clinical-stage biotechnology company focused on advancing gene therapies for severe monogenic diseases of the central nervous system. She was previously associate vice president of commercialization and business development at UT Southwestern Medical Center and vice president of venture development at Remeditex Ventures.
Dr. Aldridge currently serves on the scientific advisory board of Colossal Biosciences and on the board of directors of 4E Therapeutics. She is also a member of the Product Development Advisory Committee of the Cancer Prevention and Research Institute of
Dr. Aldridge received her PhD from Duke University in the Department of Immunology and the Program in Genetics and Genomics and her Bachelor of Science degree in Biomedical Science from Texas A&M University.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, including
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding the potential impacts of a director's appointment to the company's board of directors and expectations regarding the company's performance and success. These forward-looking statements are based on Alexandria's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.
CONTACT: Sara Kabakoff, Senior Vice President – Chief Content Officer, (626) 788-5578, skabakoff@are.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-elects-claire-aldridge-phd-to-board-of-directors-302393735.html
SOURCE Alexandria Real Estate Equities, Inc.
FAQ
When will Claire Aldridge join Alexandria Real Estate Equities (ARE) board of directors?
What committees will Dr. Aldridge serve on ARE's board?
What is Dr. Aldridge's background in life sciences?
What are Dr. Aldridge's current board positions besides ARE?
